Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical North America

Valeant CEO Timothy Tyson and President, North America Wesley Wheeler: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Execs provide an update on plans for recharging Cesamet following a sluggish launch, and development plans for a new potential entry: retigabine for seizures.

You may also be interested in...



Valeant On Track To File Retigabine For Epilepsy In 2008

Pending approval, the first-in-class neuronal potassium channel opener would launch in 2009.

Valeant On Track To File Retigabine For Epilepsy In 2008

Pending approval, the first-in-class neuronal potassium channel opener would launch in 2009.

Valeant CEO Timothy Tyson and President, North America Wesley Wheeler: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

Valeant execs outline development plans for taribavirin for hepatitis C, licensing opportunities and goals for ramping up the commercial organization ahead of potential new launches.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical North America
Latest Headlines

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

See All
UsernamePublicRestriction

Register

PS066654

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By